# US 2021/0070840 A1 · Fibronectin type iii domain proteins with enhanced solubility

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0070840 A1
- Document ID: US20210070840A1
- Status: Published application
- Kind: A1
- Application number: 16/999,291
- Filed: 2020-08-21
- Published: 2021-03-11
- Earliest claimed: 2013-02-06
- Assignees: Bristol-Myers Squibb Company
- Applicants: Bristol-Myers Squibb Company
- Inventors: Aaron P. YAMNIUK; Stanley R. KRYSTEK
- Web page: https://patentgrep.com/patent/US20210070840A1

## CPC

- C07K 14/78: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
- C12N 15/00: Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (mutants or genetically engineered microorganisms, per se C12N1/00, C12N5/00, C12N7/00; new plants per se A01H; plant reproduction by tissue culture techniques A01H4/00; new animals per se A01K67/00; use of medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases, gene therapy A61K48/00)
- C12N 2320/00: Applications; Uses
- C12N 2330/31: Libraries, arrays
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided herein are polypeptides comprising a modified fibronectin type III (Fn3) domain, wherein the amino acid corresponding to residue 58 of SEQ ID NO: 1 is mutated, and wherein the solubility is enhanced relative to the solubility of a Fn3 domain in which the amino acid corresponding to residue 58 of SEQ ID NO: 1 is not mutated. Also provided are libraries comprising a plurality of the polypeptides and a method for identifying a polypeptide that binds to a target.

## Claims

### Claim at position 1

1-40. (canceled)

### Claim 41

A nucleic acid encoding a polypeptide comprising a 10th human fibronectin type III (10Fn3) domain, wherein the amino acid in the 10Fn3 domain corresponding to residue 58 of SEQ ID NO: 1 is Glu (E), and wherein the solubility of the 10Fn3 domain is enhanced relative to the solubility of the same 10Fn3 domain wherein the amino acid corresponding to residue 58 of SEQ ID NO: 1 is Thr (T).

### Claim 42 (depends on 41)

The nucleic acid of claim 41, further comprising at least one pharmacokinetic (PK) moiety selected from the group consisting of: a polyoxyalkylene moiety, a human serum albumin binding protein, sialic acid, human serum albumin, IgG, an IgG binding protein, transferrin, an Fc, and an Fc fragment.

### Claim 43 (depends on 42)

The nucleic acid of claim 42, wherein the PK moiety is a polyoxyalkylene moiety, and wherein the polyoxyalkylene moiety is polyethylene glycol.

### Claim 44 (depends on 42)

The nucleic acid of claim 42, wherein the PK moiety is an Fc or Fc fragment.

### Claim 45 (depends on 41)

The nucleic acid of claim 41, wherein the 10Fn3 domain comprises a BC loop which has the amino acid sequence of the corresponding BC loop of the wildtype human 10Fn3 domain (SEQ ID NO: 1).

### Claim 46 (depends on 41)

The nucleic acid of claim 41, wherein the solubility of the polypeptide is determined using an ammonium sulfate solubility assay.

### Claim 47 (depends on 41)

The nucleic acid of claim 41, wherein the DE loop of the 10Fn3 domain is hydrophobic.

### Claim 48 (depends on 41)

An expression vector comprising the nucleic acid of claim 41.

### Claim 49 (depends on 41)

A host cell comprising the nucleic acid of claim 41.

### Claim 50 (depends on 48)

A host cell comprising the expression vector of claim 48.

### Claim 51 (depends on 49)

A method of producing a polypeptide comprising a 10th human fibronectin type in (10Fn3) domain comprising:
(a) culturing the host cell of claim 49 under conditions that produce the polypeptide, and
(b) isolating the polypeptide.

### Claim 52 (depends on 50)

A method of producing a polypeptide comprising a 10th human fibronectin type III (10Fn3) domain comprising:
(a) culturing the host cell of claim 50 under conditions that produce the polypeptide, and
(b) isolating the polypeptide.

### Claim 53

A method of treating a disease or disorder comprising administering to a subject in need thereof a polypeptide comprising a 10th human fibronectin type III (10Fn3) domain, wherein the amino acid in the 10Fn3 domain corresponding to residue 58 of SEQ ID NO: 1 is Glu (E), and wherein the solubility of the 10Fn3 domain is enhanced relative to the solubility of the same 10Fn3 domain wherein the amino acid corresponding to residue 58 of SEQ ID NO: 1 is Thr (T).

### Claim 54

A composition comprising a polypeptide comprising a 10th human fibronectin type HI (10Fn3) domain, wherein the amino acid in the 10Fn3 domain corresponding to residue 58 of SEQ ID NO: 1 is Glu (E), and wherein the solubility of the 10Fn3 domain is enhanced relative to the solubility of the same 10Fn3 domain wherein the amino acid corresponding to residue 58 of SEQ ID NO: 1 is Thr (T).
